SINGAPORE – A novel allosteric fibroblast growth factor receptor 2 (FGFR2) inhibitor, alofanib, has potent anti-tumour and antiangiogenic activity, according to the results of preclinical studies. The results were presented at the ESMO Asia 2016 Congress...
Dmitry Medvedev visited the first Skolkovo’s Innovation City building, the “Hypercube”, held the Modernization and Innovations Council meeting there and made a brief welcome speech at a biomed conference, held by the Skolkovo Foundation there...
The Skolkovo Institute of Science and Technology has announced a new program in Biomedical Science and Technology to educate leading graduate students. The university is inviting applications from entrepreneurial scientists in Russia and abroad for the 2013...